Navigation Links
US HIFU Announces Name Change To SonaCare Medical

CHARLOTTE, N.C., Feb. 21, 2013 /PRNewswire/ -- USHIFU, LLC (US HIFU), a global leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that it has changed the company's name to SonaCare Medical, LLC (SonaCare Medical).  Effective immediately, US HIFU will function as SonaCare Medical and all subsidiaries and operating units, including International HIFU and Focus Surgery, will be rebranded to reflect their relationship to SonaCare Medical.  

"The company was renamed SonaCare Medical to better align with our strategic vision of expanding our current HIFU technology to treat a range of urological indications that, like our prostate cancer application, balances both treatment effectiveness and quality of life," said Michael Klein , CEO of SonaCare Medical.  "This also enables us to streamline our global operations and focus our development and regulatory efforts to expand the application of our suite of HIFU technologies, which have been used to treat more than 12,000 patients worldwide."

SonaCare Medical's vision is to develop HIFU surgical ablation systems for a wide range of urological indications, in addition to prostate cancer, that allows for tissue targeting techniques. SonaCare Medical's HIFU surgical systems are the only ablative technologies to utilize T3 Technology™, which enables physicians to: target selected tissue with customized planning and sophisticated localization tools; treat targeted tissue accurately and reliably with robotic precision, while sparing tissue outside the ablation zone; and track the HIFU procedure with advanced real-time ultrasound imaging and unique tissue monitoring technologies.

"The field of urologic oncology has embraced the concept of tissue-sparing approaches to cancer treatment, provided therapeutic efficacy is not compromised," says Mark Schoenberg , MD, Chief Medical Officer at SonaCare Medical. "A critical feature of image-guided surgery is the ability to localize and verify ablation of the therapeutic target in real-time.  The HIFU systems from SonaCare Medical combine three capabilities into one single operating platform; integrated imaging, precision ablation and real-time tissue change validation."

SonaCare Medical's proprietary HIFU systems deliver therapy that destroys targeted tissue with rapid heat elevation. HIFU concentrates high frequency ultrasound waves from a transducer (which focuses sound much like a magnifying glass focuses light) into a small ablation zone. At the ablation zone, the temperature rapidly raises causing complete cellular necrosis, destroying all targeted tissue while leaving untargeted tissue unharmed.

"Our approach to the thermal ablation market is very unique," says Mark Carol , M.D., Chief Development Officer for SonaCare Medical. "The result is a family of HIFU ablation systems that combine the best aspects of minimally invasive robotic surgery and the treatment planning elements of image guided radiation therapy."

SonaCare Medical, through its subsidiary Focus Surgery, Inc., manufactures the HIFU systems. Sonatherm® laparoscopic HIFU surgical ablation system is 510(k) cleared in the United States. Sonablate® 450 is approved for investigational use within the U.S. and is being studied in a clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy.  Sonablate® 500 has CE Marking, has an installed base of more than 130 systems and is, or has been, approved for use in more than 30 countries outside the U.S. for the treatment of prostate cancer.

"To help fund the continued development of SonaCare Medical's HIFU surgical ablation systems, the completion of our FDA filings and to prepare for the commercialization of new products, the company completed financings totaling $17 million in 2012," Klein added.  "This further validates our market leadership and puts the company in a strong position to achieve our goals of expanding our technology to a wide range of urological indications."

About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial; Sonablate® 500 which has CE Marking and is, or has been, approved for use in more than 30 countries outside the U.S.; and Sonatherm® which is 510(k) cleared. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S.

SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C. Additional information may be found at

SOURCE SonaCare Medical, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
Breaking Medicine News(10 mins):